Ranjit Dhaliwal, MD
Retina Specialist · Augusta, GANPI 1851387245
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (47.2%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 76.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $11,179 and has fallen 96.6% since, to $378 in 2025.
Across 75 payments — averaging $234.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$14K
- Alimera Sciences, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$546
- Genentech USA, Inc.$480
- Astellas Pharma US Inc$370
- Kala Pharmaceuticals, Inc.$231
- plus $956 from 16 others
What the payments were for
- Travel & lodging$1,3117%
- Food & beverage$2,78316%
- Ownership interest$5,20230%
- Other$8,31547%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $13,516 |
| Alimera Sciences, Inc. | 3 | $1,511 |
| Regeneron Healthcare Solutions, Inc. | 10 | $546 |
| Genentech USA, Inc. | 14 | $480 |
| Astellas Pharma US Inc | 6 | $370 |
| Kala Pharmaceuticals, Inc. | 4 | $231 |
| Bausch & Lomb Americas Inc. | 4 | $161 |
| Dutch Ophthalmic, USA | 3 | $136 |
| AbbVie | 1 | $125 |
| Biogen | 5 | $107 |
| Coherus Oncology, Inc. | 4 | $92 |
| Apellis Pharmaceuticals, Inc. | 3 | $63 |
| Eyevance Pharmaceuticals LLC | 3 | $45 |
| Topcon Healthcare, Inc. | 1 | $43 |
| Sandoz | 1 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Harrow Eye, LLC | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Novartis | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $16 |
| Alcon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 292 | $15,631 |
| Loteprednol Etabonate | 55 | $11,759 |
| Dorzolamide Hcl | 272 | $6,008 |
| Ciprofloxacin Hcl | 418 | $4,956 |
| Fluorometholone | 45 | $4,503 |
| Ketorolac Tromethamine | 153 | $4,161 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $3,202 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $3,104 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 129 | $2,153 |
| Latanoprost | 133 | $1,563 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 29 | $1,320 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 90 | $1,133 |
| Brimonidine Tartrate | 95 | $1,114 |
| Timolol Maleate | 99 | $961 |
| Acetazolamide ErAcetazolamide | 17 | $483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $22 | $11,75955 claims |
| AbbVieCombigan | $125 | $3,10413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other retina specialist in Augusta
- Oksana DemediukAugusta$16K
- Sohail KhanAugusta$3K
- Diego Espinosa-HeidmannAugusta$2K
- Julian NussbaumAugusta$891
- David Chin YeeAtlanta$816K
- Daniel OhAtlanta$58K
- Sruthi ArepalliAtlanta$30K
- Alexander BottiniBraselton$7K
- Kareem SioufiMarietta$6K
- James FrankAtlanta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.